Quick Takeaways
- Caligan Partners LP filed SCHEDULE 13G/A for Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share (AVTX).
- Disclosed ownership: 4.9%.
- Date of event: 31 Dec 2025.
Caligan Partners LP - 31 Dec 2025 SCHEDULE 13G/A Report for Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share (AVTX)
- Filing Manager
- Caligan Partners LP
- Reporting Manager
- Caligan Partners LP
- Symbol
- AVTX
- Shares outstanding
- 17,990,469 shares
- Disclosed Ownership
- 881,533 shares
- Ownership
- 4.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 17:00:13 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 14 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Caligan Partners LP disclosed 4.9% ownership in Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share (AVTX) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 14 Nov 2025.
- Current filing was accepted on 17 Feb 2026, 17:00.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Caligan Partners LP | 4.9% | 881,533 | 0 | 881,533 | /s/ David Johnson | David Johnson, Managing Partner | |
| David Johnson | 4.9% | 881,533 | 0 | 881,533 | /s/ David Johnson | David Johnson, Managing Partner |